Leigh Farrell brings over 30 years of leadership experience across the biotechnology, pharmaceutical, and medical technology sectors. He is the Managing Director of AdNED Pty Ltd and serves as a Non-Executive Director of Pro Medicus Ltd, where he is a member of both the Risk and Audit Sub-Committee and the People and Culture Sub-Committee.
Leigh also holds board and advisory roles with several innovative health and medical research organisations. He is a board member of Ena Respiratory and Axelia Oncology Pty Ltd, and sits on the Commercialisation Committee of the Walter and Eliza Hall Institute of Medical Research. Additionally, he serves on the Scientific and Industry Advisory Committee of the Australian Research Council Centre for Cryo-electron Microscopy of Membrane Proteins and is a member of the Investment Review Committee for the CUREator+ Dementia and Cognitive Decline program, funded by the Medical Research Future Fund.
Previously, Leigh led Health Security Systems Australia, a division of DMTC Ltd, where he oversaw strategic advisory and program management focused on national preparedness and response to chemical, biological, radiological, and nuclear (CBRN) threats. Earlier in his career, he was Senior Vice President, Commercial at Certara USA, Inc., responsible for commercial operations across the Asia Pacific region. This followed his role as Chairman and Chief Operating Officer of d3 Medicine LLC, which was later acquired by Certara.
Leigh has also held senior roles as Vice President of Business Development at Biota Pharmaceuticals, Associate Director at GBS Venture Partners, Research Manager at Johnson & Johnson Research, and CEO of Gene Shears Pty Ltd.
He is a Fellow of the Australian Institute of Company Directors.
Already a member?
Login to view this content